Feed GOVX
GO

GeoVax Labs, Inc.

GOVX · NASDAQ

$0.46 -3.54% (-$0.02)
1M -35.52%
Market Cap $3.43M
P/E Ratio -
Div. Yield -
ROE 743.66%
Piotroski F-Score Weak
2/9
Valuation
89 /100
Cheap
P/B 1.95x
EV/EBITDA N/A
P/S N/A
Growth
78 /100
Growing
Book val. growth 47.61%
Rev. growth 212.55%
FCF growth N/A
Profitability
-
N/A
Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor
ROE 743.66%
ROA 439.95%
Asset turnover 0.00x
Debt
92 /100
Low
Current ratio 1.54x
Debt/Equity 0.18x
Net debt/EBITDA N/A
Stability
1 /100
Unstable
EPS volatility 89.07%
Profitable years 0
Beta 3.65x

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre GOVX
Online

Despre companie

GeoVax Labs (GOVX) is a biotechnology company focused on the development of vaccines for the prevention and treatment of infectious diseases, such as HIV/AIDS, Ebola, Zika virus, and others. Using its patented technological approach, GeoVax develops vaccines aimed at providing effective protection against dangerous pathogens. The company also focuses on vaccine development for emerging threats in public health, including COVID-19. GeoVax Labs (GOVX) shares could be suitable for investors seeking opportunities in the biotechnology sector with a focus on vaccine research and development.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

David Alan Dodd

Employees

19

Headquarters

Smyrna

Evenimente viitoare

12 NOV.

Earnings

Upcoming earnings report

60d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.